What type of study is this?

October 18, 2025CancersOpen Access

Neoadjuvant 177Lutetium-PSMA-617 Radioligand Therapy for High-Risk Localized Prostate Cancer: Rationale, Early Clinical Evidence, and Future Directions

View Full Paper

Ask AI

Bookmark

Authors

Early clinical evidence supports 177lutetium-psma-617 therapy for localized prostate cancer, suggesting improvements may lead to better outcomes.

Radioligand therapy promotes immunogenic cell death and may enhance the effectiveness of checkpoint inhibitors in localized prostate cancer.
Initial trials show 177lutetium-psma-617's feasibility and safety, yet a pathological complete response remains elusive in many cases.
There is pressing need for validated surrogate endpoints and predictive biomarkers to properly assess treatment success in clinical settings.
Large-scale randomized trials are essential to verify whether this investigational approach improves key outcomes like metastasis-free survival.

Kwon et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Early clinical evidence supports 177lutetium-psma-617 therapy for localized prostate cancer, suggesting improvements may lead to better outcomes.